Brain organoid reveals Parkinson’s cell mechanism
Parkinson’s disease has long been difficult to study in the lab: animal models only partially replicate the human condition.
Gaucher disease is a hereditary metabolic disorder in which a specific enzyme inside cells does not function properly. In its severe form, brain cells are affected. People with Gaucher disease and certain genetic variants also face an elevated risk of Parkinson’s disease. That makes Gaucher disease a useful model for understanding the early stages of Parkinson’s.
Researchers described in eLife how they created brain organoids (small three-dimensional tissue structures grown from human stem cells) using cells from patients with Gaucher disease. They then corrected the genetic defect using CRISPR (a technique that can precisely repair a genetic error in DNA). The study shows that the corrected organoids restored enzyme activity and that dopaminergic neurons (brain cells that produce dopamine and are lost in Parkinson’s disease) developed normally.
A platform for testing new treatments
The platform was also used to test three different treatment strategies. One approach used nanovesicles (small spherical carriers that deliver the missing enzyme to the cell). A second was an AAV gene therapy placing a functional gene inside the cell. A third inhibited the production of the harmful accumulating substance. All three improved certain disease features in the organoids, including enzyme activity, lipid accumulation, and gene expression patterns.
This type of organoid model bridges an important gap in drug development. Animal models of Parkinson’s are limited because mouse brains experience the disease differently. Studying human brain cells directly in the lab had previously not been reliably possible. Organoids offer a middle ground.
Early stage, but methodologically strong
This is laboratory research. Organoids are a simplified version of human brain tissue without blood vessels, immune cells, or normal environmental signals. Whether therapies that work here will also work in a living brain remains to be seen. But the combination of patient-specific models, CRISPR correction, and simultaneous therapy testing makes this a methodologically solid step forward.